Clinical significance of hormone receptor status detection in simultaneous axillary metastasis for hormone receptor-negative primary breast cancer patients

Chinese Journal of Clinical Oncology

Volumn 40, Issue 15, 2013, Pages 911-913

  Jin, Liangbin ^a   Yao, Zixiang ^a   Kong, Lingquan ^a   Li, Hongyuan ^a   Wu, Kainan ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Axillary lymph node metastasis; Breast cancer; Endocrine therapy; Hormone receptor negative

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; FOLLOW UP; HORMONAL THERAPY; HUMAN; IMMUNOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION;

EID: 84885148684     PISSN: 10008179     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1000-8179.2013.15.008     Document Type: Article

References (15)

1. Coleman MP, Forman D, Bryant H, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data[J]. Lancet, 2011, 377(9760):127-138.
2. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer[J]. J Clin Oncol, 2010, 28(23):3784-3796.
3. Lindstrom LS, Karlsson E, Wilking UM, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression[J]. J Clin Oncol, 2012, 30(21):2601-2608.
4. Dieci MV, Barbieri E, Piacentini F, et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single - Institution analysis[J]. Ann Oncol, 2013, 24(1):101-108.
5. Toni I, Alberto F, Emanuela S, et al. Hormonal Receptor, Human Epidermal Growth Factor Receptor-2, and Ki67 Discordance between Primary Breast Cancer and Paired Metastases[J]. Clin Imp Oncol, 2013, 84:150-157.
6. Jensen JD, Knoop A, Ewertz M, et al. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer[J]. Bre Can Res Tre, 2012, 132(2):511-521.
7. Nedergaard L, Haerslev T, Jacobsen GK. Immunohistochemical study of estrogen receptors in primary breast carcinomas and their lymph node metastases including comparison of two monoclonal antibodies[J]. APMIS, 1995, 103:20-24.